Shenkang Injection Prevents Contrast-Induced Nephropathy by Regulating Ferroptosis Via the STAT3/HIF-1α/HMOX-1 Pathways - PubMed
5 hours ago
- #STAT3/HIF-1α/HMOX-1 pathway
- #contrast-induced nephropathy
- #ferroptosis
- Shenkang Injection (SKI) prevents Contrast-Induced Nephropathy (CIN) by regulating ferroptosis via the STAT3/HIF-1α/HMOX-1 pathways.
- CIN is the third most common cause of acute renal damage in inpatient settings, with scarce effective therapies and uncertain pathophysiology.
- Network pharmacology identified 15 potential ferroptosis-related targets of SKI for preventing CIN, with the HIF-1 signaling pathway playing a critical role.
- In vivo experiments showed that contrast agents induce CIN under specific conditions, with biomarkers and electron microscopy supporting ferroptosis occurrence.
- Ferrostatin-1 (Fer-1) and SKI treatment downregulated STAT3, HIF-1α, and HMOX-1, mitigating CIN by suppressing ferroptosis.
- SKI reduces ferroptosis in HK-2 cells induced by contrast medium, suggesting its potential as an effective multi-target therapy for CIN.